Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients

Sher Ting Chim; Paul Sanfilippo; Terence J O'Brien; Kate J Drummond; Mastura Monif

doi:10.1016/j.jneuroim.2021.577754

Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients

J Neuroimmunol. 2021 Dec 15:361:577754. doi: 10.1016/j.jneuroim.2021.577754. Epub 2021 Oct 19.

Authors

Sher Ting Chim¹, Paul Sanfilippo², Terence J O'Brien³, Kate J Drummond⁴, Mastura Monif⁵

Affiliations

¹ Faculty of Medicine, Nursing and Health Sciences, Monash University, 27 Rainforest Walk, Clayton, VIC 3800, Australia; Melbourne Brain Centre, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3052, Australia; Department of Neurology, Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia. Electronic address: schi0017@student.monash.edu.
² Department of Neuroscience, Monash University, Melbourne, VIC 3000, Australia. Electronic address: paul.sanfilippo@monash.edu.
³ Faculty of Medicine, Nursing and Health Sciences, Monash University, 27 Rainforest Walk, Clayton, VIC 3800, Australia; Melbourne Brain Centre, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3052, Australia; Department of Neurology, Alfred Health, Prahran, Melbourne, VIC 3000, Australia; Department of Neuroscience, Monash University, Melbourne, VIC 3000, Australia. Electronic address: terence.obrien@monash.edu.
⁴ Department of Neurosurgery, The University of Melbourne, Parkville, VIC 3050, Australia; Department of Neurosurgery, Royal Melbourne Hospital, Parkville, VIC 3050, Australia. Electronic address: Kate.Drummond@mh.org.au.
⁵ Faculty of Medicine, Nursing and Health Sciences, Monash University, 27 Rainforest Walk, Clayton, VIC 3800, Australia; Melbourne Brain Centre, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3052, Australia; Department of Neurology, Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia; Department of Neurology, Alfred Health, Prahran, Melbourne, VIC 3000, Australia; Department of Neuroscience, Monash University, Melbourne, VIC 3000, Australia. Electronic address: mastura.monif@monash.edu.

PMID: 34700046
DOI: 10.1016/j.jneuroim.2021.577754

Abstract

Objectives: To evaluate the ability for pre-treatment NLR and MLR to predict overall survival (OS) and modified Rankin Scale (mRS) and to explore their relationship with clinicopathological parameters.

Methods: Retrospective analysis of pretreatment NLR and MLR from 64 glioma patients.

Results: Higher pretreatment NLR (>4.7) predicted higher mean admission mRS (p < 0.001) and 6-month mRS (p = 0.02). Higher pretreatment MLR (>0.35) was a risk factor for poorer OS in glioma patients (p = 0.024). Higher pretreatment NLR was significantly associated with larger tumor diameter (p = 0.02).

Conclusion: NLR and MLR can serve as prognostic markers to predict functional outcomes and OS in glioma patients.

Keywords: MLR; NLR; glioma; prognosis.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Area Under Curve
Biomarkers
Brain Neoplasms / blood*
Brain Neoplasms / mortality
Female
Glioma / blood*
Glioma / mortality
Humans
Kaplan-Meier Estimate
Leukocyte Count*
Lymphocyte Count
Male
Middle Aged
Monocytes*
Neutrophils*
Prognosis
ROC Curve
Retrospective Studies
Young Adult

Substances

Biomarkers